CA2049964A1 - Proteines hybrides de la proteine de liaison de c4 - Google Patents

Proteines hybrides de la proteine de liaison de c4

Info

Publication number
CA2049964A1
CA2049964A1 CA002049964A CA2049964A CA2049964A1 CA 2049964 A1 CA2049964 A1 CA 2049964A1 CA 002049964 A CA002049964 A CA 002049964A CA 2049964 A CA2049964 A CA 2049964A CA 2049964 A1 CA2049964 A1 CA 2049964A1
Authority
CA
Canada
Prior art keywords
c4bp
protein
polypeptide
human
multimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002049964A
Other languages
English (en)
Inventor
Mark P. Pasek
Gunther Winkler
Theresa R. Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2049964A1 publication Critical patent/CA2049964A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70514CD4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002049964A 1990-01-26 1991-01-28 Proteines hybrides de la proteine de liaison de c4 Abandoned CA2049964A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47088890A 1990-01-26 1990-01-26
US470,888 1990-01-26
PCT/US1991/000567 WO1991011461A1 (fr) 1990-01-26 1991-01-28 Proteines de fusion de proteines liantes c4

Publications (1)

Publication Number Publication Date
CA2049964A1 true CA2049964A1 (fr) 1991-07-27

Family

ID=23869471

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002049964A Abandoned CA2049964A1 (fr) 1990-01-26 1991-01-28 Proteines hybrides de la proteine de liaison de c4

Country Status (5)

Country Link
EP (1) EP0465633A1 (fr)
JP (1) JPH04506460A (fr)
AU (1) AU7328891A (fr)
CA (1) CA2049964A1 (fr)
WO (1) WO1991011461A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05508779A (ja) * 1991-03-12 1993-12-09 バイオジェン,インコーポレイテッド リンパ球機能関連抗原3のcd2結合ドメイン
MX9203138A (es) * 1991-03-12 1992-09-01 Biogen Inc Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5869624A (en) * 1993-03-26 1999-02-09 Progenics Pharmaceuticals, Inc. HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
FR2736916B1 (fr) 1995-07-21 1997-09-19 Univ Paris Curie Proteines hetero-multimeriques recombinantes du type alpha-beta c4bp
WO1999044625A1 (fr) 1998-03-03 1999-09-10 John Hopkins University Inhibiteur d'enzymes de complement, derive du virus de la variole (spice), proteines liees au spice et methode d'inhibition de l'activation du complement
JP2002512261A (ja) * 1998-04-15 2002-04-23 ベルクター,ヴォルフガンク Hiv感染を治療するためのcd4放射免疫薬
AU4770300A (en) * 1999-05-14 2000-12-05 Medical Research Council Protein scaffold and its use to multimerise monomeric polypeptides
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1419236A4 (fr) 2001-07-24 2005-08-03 Biogen Idec Inc Methodes de traitement ou de prevention de troubles sclereux par l'usage d'agents se liant a cd2
AU2003219732A1 (en) * 2002-02-11 2003-09-04 Institut De Recherches Cliniques De Montreal Oligomeric molecules and uses thereof
EP1529109A2 (fr) * 2002-08-14 2005-05-11 Avidis SA Production de proteines de fusion multimeres utilisant un echafaudage c4bp
CA2494971A1 (fr) * 2002-08-14 2004-02-26 Avidis Sa Complexes multimeres d'antigenes et d'adjuvants
JP2007528210A (ja) * 2003-08-12 2007-10-11 アヴィディス エスアー C4bpコアタンパク質及び単量体抗原を含む生成物及びその使用
WO2005051414A1 (fr) * 2003-11-26 2005-06-09 Avidis Sa Utilisation de la zone nucleique c4bp comme agoniste de cd40
WO2005077976A2 (fr) * 2004-02-13 2005-08-25 Avidis Sa Domaines bispirales
EP1750747A1 (fr) 2004-05-07 2007-02-14 Astellas US LLC Polypeptide lfa-3 soluble destine a traiter de troubles viraux
EP1790358A1 (fr) * 2005-11-23 2007-05-30 Université de Reims Champagne-Ardennes Constructions protéiques concues pour cibler et lyser des cellules
EP1795540A1 (fr) * 2005-11-30 2007-06-13 Imaxio Complexes multiples d'antigènes et d'un adjuvant
GB0918154D0 (en) * 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
EP2557089A2 (fr) * 2011-07-15 2013-02-13 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compositions et procédés d'immunomodulation
EP3273990A4 (fr) 2015-03-24 2018-11-14 Fred Hutchinson Cancer Research Center Glycoprotéines d'enveloppe du virus de l'immunodéficience humaine multimérisées et ingéniérisées et leurs utilisations
WO2017083545A1 (fr) 2015-11-10 2017-05-18 Fred Hutchinson Cancer Research Center Leurres nkg2d
US11707505B2 (en) 2019-11-15 2023-07-25 King Faisal Specialist Hospital & Research Centre VCP and factor H as viral entry inhibitors

Also Published As

Publication number Publication date
AU7328891A (en) 1991-08-21
JPH04506460A (ja) 1992-11-12
EP0465633A1 (fr) 1992-01-15
WO1991011461A1 (fr) 1991-08-08

Similar Documents

Publication Publication Date Title
CA2049964A1 (fr) Proteines hybrides de la proteine de liaison de c4
Lasky et al. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor
Zettlmeissl et al. Expression and characterization of human CD4: immunoglobulin fusion proteins
EP0325262B1 (fr) Gènes clonés encodant des protéines fusionnées Ig-CD4 et leur utilisation
JP4642035B2 (ja) Aids、arcおよびhiv感染の予防および治療に有用な抗cd4抗体ホモログ
EP0394827A1 (fr) Polypeptides chimériques de CD4-immunoglobuline
KR100547049B1 (ko) 바이러스 감염증 치료를 위한 조성물 및 방법
CA1330038C (fr) Methode et compositions pour l'utilisation des polypeptides env de vih et anticorps diriges contre ces polypeptides
EP0687183A1 (fr) Composition synergique d'une proteine a base de cd4 et d'un anticorps dirige contre le vih-1, et procedes d'utilisation
NZ226040A (en) T-cell specific antigens, dna and pharmaceutical compositions
EP1340769B1 (fr) Chimères de CD4-gamma2 et de CD4-IgG2
EP0414178A2 (fr) Polypeptides CD4 de primates non humains et molécules CD4 humaines susceptibles d'être glycosylées
CA2078545A1 (fr) Polypeptides de l'enveloppe de vih
IL91070A (en) Cytotoxic agents against certain viral infections
WO1992013559A1 (fr) CHIMERES DE CD4-GAMMA1 ET DE CD4-IgG1
Howie et al. Synthetic peptides representing discontinuous CD4 binding epitopes of HIV‐1 gp120 that induce T cell apoptosis and block cell death induced by gp120
US7070991B2 (en) Cells expressing a CD4-IgG2 chimeric heterotetramer
US20030211470A1 (en) CD4-IgG2-based salvage therapy of HIV-1 infection
AU623924B2 (en) Cytotoxic agent against specific virus infection
WO1990000566A1 (fr) Inhibition d'infection par vih-1 a l'aide de cd4 soluble
AU611551C (en) Cloned genes encoding IG-CD4 fusion proteins and the use thereof
Agentsa Implications for the Design of Small-Peptide
JP2009082135A (ja) Aids、arcおよびhiv感染の予防および治療に有用な抗cd4抗体ホモログ
JPH03504802A (ja) 特定のウイルス感染に対する細胞毒性剤

Legal Events

Date Code Title Description
FZDE Dead